Table 2.
Advantages | |
Whole brain atrophy is easy to measure | |
Brain atrophy is a “summary measure” of the irreversible/destructive pathological process of MS | |
Whole brain atrophy is highly reproducible and sensitive to disease-related changes | |
Correlates with disability, cognitive impairment and fatigue | |
Disadvantages: | |
End-stage phenomenon | |
Pseudoatrophy effect (first 6–12 months) | |
Fluctuations: steroids, hydration | |
Co-morbidities: smoking, alcohol, high BMI, etc. | |
MRI technical confounding factors | |
Time consuming: reimbursement? | |
Not enough evidence to use atrophy measures to assess and predict individual treatment response |
BMI Body Mass Index